Bristol-Myers’ Yervoy hopes snag on flubbed prostate cancer trial

Bristol-Myers Squibb has hit a speed bump in the road to new uses for its melanoma treatment Yervoy. The drug fell short in a prostate cancer trial, by failing to significantly extend patients' lives.
Read the full story: FiercePharma News